Structure Therapeutics (NASDAQ:GPCR) Price Target Cut to $110.00 by Analysts at Citizens Jmp

Structure Therapeutics (NASDAQ:GPCR) had its price target cut by Citizens Jmp from $113.00 to $110.00 in a research note published on Friday,Benzinga reports. They currently have a market outperform rating on the stock.

Other research analysts have also recently issued research reports about the company. Wall Street Zen upgraded Structure Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 1st. HC Wainwright lowered their target price on Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating for the company in a research note on Thursday, June 11th. Canaccord Genuity Group set a $111.00 target price on Structure Therapeutics in a report on Friday. Citigroup reissued a “market outperform” rating on shares of Structure Therapeutics in a research report on Friday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a report on Friday, July 17th. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $110.91.

Structure Therapeutics Trading Up 1.0%

Shares of GPCR stock opened at $53.14 on Friday. The company’s fifty day simple moving average is $47.63 and its 200-day simple moving average is $54.19. Structure Therapeutics has a 52 week low of $15.86 and a 52 week high of $94.90. The company has a market cap of $3.78 billion, a PE ratio of -53.14 and a beta of -1.43.

Structure Therapeutics (NASDAQ:GPCR) last posted its earnings results on Thursday, August 6th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.10). Equities research analysts expect that Structure Therapeutics will post -1.64 EPS for the current fiscal year.

Institutional Trading of Structure Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Handelsbanken Fonder AB acquired a new position in shares of Structure Therapeutics in the second quarter worth about $1,041,000. Seven Fleet Capital Management LP acquired a new stake in Structure Therapeutics during the 1st quarter valued at approximately $434,000. Avidity Partners Management LP acquired a new stake in Structure Therapeutics during the 1st quarter valued at approximately $1,446,000. Bank of America Corp DE increased its holdings in Structure Therapeutics by 617.0% during the 1st quarter. Bank of America Corp DE now owns 227,132 shares of the company’s stock worth $10,948,000 after purchasing an additional 195,454 shares during the last quarter. Finally, Janus Henderson Group PLC increased its holdings in Structure Therapeutics by 5.2% during the 1st quarter. Janus Henderson Group PLC now owns 5,354,981 shares of the company’s stock worth $258,260,000 after purchasing an additional 264,833 shares during the last quarter. 91.78% of the stock is owned by hedge funds and other institutional investors.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.